Affiliated to
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gemelli Digital Medicine & Health (GDMH), a company fully owned by Fondazione Policlinico Gemelli, develops digital medicine solutions to enhance healthcare efficiency. We support hospitals, research centers, and biotech companies with advisory services and tech-bio platforms that blend clinical expertise and digital innovation. Our offerings include advanced e-health tools, AI-driven diagnostics, and transformation accelerators. Unique in combining Fondazione Policlinico Gemelli’s know-how with proprietary accelerators and industry partnerships, we place specialists at the center of ideation, development, and industrialization of solutions defining future healthcare research and delivery. We are partners in European projects such as Horizon 2020 and the Innovative Health Initiative (IHI).
Role within INTERCEPT
Gemelli Digital Medicine & Health (GDMH) plays a key role in the INTERCEPT project by leading efforts in digital health innovation and translational research. GDMH investigates biological mechanisms driving the shift from health to Crohn’s disease and defines target profiles for early-diagnosis biomarkers and new intervention strategies. It also structures knowledge around biomarker use through adverse outcome pathways. Additionally, GDMH is responsible for developing a digital platform, “e-INTERCEPT,” to support clinical decision-making through integrated data collection and analysis. It contributes to regulatory strategy, drafting guidance for biomarker qualification with authorities such as EMA and FDA. GDMH also supports the design of the project’s digital infrastructure, promoting interoperability and federated data analysis across partners.
Main contacts
Dr Alfredo Cesario
CEO Cardiothoracic Surgeon
Rebecca Iacopini
Project Manager Biomedical Engineer
Marta Onniboni
Project Manager Biomedical Engineer
Jacopo Salomone
Project Manager IT manager
Giovanna Giuffrè
Senior Project Manager
Elena Fiorelli
Data Scientist Biotechnologist